Must be local to New York City and work from the midtown office.
Vendelux offers a subscription-based platform that provides a searchable database of over 160,000 B2B events and 10 million attendee and company profiles to help teams plan event marketing. Users research and filter events, receive data-driven recommendations on where to attend or sponsor, and use built-in tools to connect with key decision-makers and measure ROI for executives. It differentiates itself by delivering continuously updated, cross-functional data that supports sales and marketing coordination and ROI justification beyond traditional search methods. The goal is to help businesses choose the right events, generate leads, strengthen brand presence, and prove measurable ROI to executives.
Company Size
51-200
Company Stage
Series B
Total Funding
$68M
Headquarters
New York City, New York
Founded
2021
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Unlimited Paid Time Off
Paid Vacation
Cold email vs pre-event outreach: which actually books conference meetings. 19 August 2026 Key takeaways. * Cold email reply rates run 3 to 5 percent for a well-run campaign, and convert leads to meetings at just 1 to 3 percent * Signal-based outbound reaches 15 to 25 percent reply rates, roughly 4 to 7 times the cold baseline, according to a synthesis of 2026 outbound benchmark data * Inbound and other high-context leads convert to meetings at 15 to 25 percent versus 1 to 3 percent cold, the same order-of-magnitude gap from an independent source * One vendor's data (Vendelux, flagged) puts pre-event outreach at 10 to 15 percent booking conversion in a 4 to 6 week window, against 1 to 3 percent once the event app is the only signal * The fix is having the attendee list scored before that 4 to 6 week window opens, not sending more volume once it closes What's a normal cold email reply rate right now? Somewhere between disappointing and fine. Apollo's 2026 benchmark work puts a well-run cold campaign at 3 to 5 percent reply rate, with top performers reaching 8 to 12 percent, and treats 10 percent or higher as excellent, a tier it associates mostly with signal-triggered sends rather than generic blasts. TAM to Target's SDR benchmark data puts it more bluntly on the metric that actually matters commercially: cold outbound converts a lead to a booked meeting at just 1 to 3 percent. An SDR has to dial or send at serious volume to produce a handful of real opportunities from that base rate. Why does adding one real signal change the math this much? Because a cold recipient has given no indication they want to talk to you, and a signal-based recipient has. A synthesis of 2026 outbound benchmark data (Instantly, Backlinko, Belkins) shows signal-based outbound reaching 15 to 25 percent reply rates, with the best teams passing 30 percent, roughly 4 to 7 times the cold baseline. One documented comparison: a team sending 10,000 cold emails booked 23 meetings. A team sending 500 signal-based emails booked 47, more meetings from 2 percent of the send volume. TAM to Target's own numbers show the same shape from a different angle: cold outbound converts leads to meetings at 1 to 3 percent, inbound (a lead who has already raised a hand) converts at 15 to 25 percent. Different studies, same order-of-magnitude gap. Signal beats volume. Does a confirmed conference attendance count as that kind of signal? It has a real case for being one of the strongest signals available, stronger than most intent data, because it is a committed behavior, not a browsing pattern. Someone who is attending a specific conference has already cleared a multi-day block on their calendar, gotten travel approved, and told their team where they'll be. That is a bigger tell than a website visit or a content download. One vendor's analysis of this specifically, Vendelux, a company that competes directly with Sideroom on pre-event attendee intelligence and is flagged here accordingly, found pre-event outreach starting 4 to 6 weeks before an event converting 10 to 15 percent to booked meetings, against 1 to 3 percent for outreach that waits until the event's own networking app opens. Treat the exact numbers as one vendor's data, not an independently verified industry figure. But the shape of it, meaningfully higher conversion when outreach starts early and references the specific event, matches the general signal-based pattern above closely enough to trust the direction even if the precise percentages need a grain of salt. Why does waiting for the event app lose the meeting? Because by the time most event apps open, typically in the final one to two weeks before the show, the calendars of the people worth meeting are largely set. Senior buyers plan travel and meetings weeks in advance, not days. An outreach message that shows up once the app is live is competing with everyone else who had the same idea at the same time, in a shrinking number of open slots. An outreach message that shows up 4 to 6 weeks out is competing with almost nobody, because almost nobody has started yet. What does a realistic pre-event outreach timeline actually look like? | Outreach window | What tends to happen | | 4 to 6 weeks before the event | Highest conversion window. Calendars still open, recipient has committed to attending but hasn't been contacted by every other exhibitor yet | | 1 to 3 weeks before the event | Still workable, but competing with a rising volume of other outreach referencing the same show | | Week of the event or once the app opens | Conversion odds fall toward cold-outbound territory. Most useful calendar slots are already gone | What should replace "wait and see who's on the app"? Know who is actually attending before that window opens, and start the outreach while the calendar is still open. That requires having the attendee list, or a scored version of it, weeks before the show rather than days before. Most teams don't have that, so they default to waiting, which is exactly the behavior that drops conversion from double digits to low single digits. The channel was never the problem. Cold email and pre-event outreach can use identical copy, the difference is whether the recipient has a reason to say yes before you ever hit send. Book against a scored list early and the constraint stops being reply rate and becomes how many of those meetings you can actually run in a day. Faq. Is pre-event outreach actually better than cold email? Directionally yes, and by a meaningful margin according to available data. The mechanism is the same one that makes any signal-based outreach outperform cold: the recipient already has a real reason to respond, in this case a confirmed conference commitment, rather than being asked to invent one. How many weeks before a conference should outreach start? 4 to 6 weeks out is the window with the best documented conversion. Waiting until the event's official app opens, typically 1 to 2 weeks out, means competing for calendar slots that are largely already filled. What if I don't know who's attending yet? That's the actual bottleneck for most teams, not the outreach copy. Without a scored attendee list, the outreach has nothing to reference and nothing to time against, which is why the app becomes the default trigger even though it's the worst-performing one.
Vendelux, a live events information platform, has raised $50 million in Series B funding led by Tribeca Venture Partners. The startup has now raised $71 million to date. The company uses AI and proprietary data from over 250,000 events globally to help B2B brands determine which events to attend and coordinate meetings. It integrates with customer relationship management systems to track whether attending specific events translates into actual deals. Founded in 2021 by Shutterstock alums Alex Reynolds and Stefan Deeran, Vendelux now serves over 250 customers, including Ramp, ElevenLabs, GitLab, DocuSign and Intel. The company plans to roughly double its staff of 85 this year, focusing on serving enterprise clients. Organizations typically spend more than one-fourth of their marketing budgets on events, according to Forrester research.
Vendelux, an AI-powered event intelligence platform, has raised $14 million in a Series A round led by FirstMark Capital, with participation from Cervin Ventures and founders of major events including HLTH, ShopTalk and Money20/20. The company's customers include PayPal, MongoDB, Calendly and T-Mobile. The platform uses artificial intelligence and predictive modelling to help event marketers analyse customer and competitor behaviour across 160,000 global events. With 65 million data points and deep CRM integrations, Vendelux enables companies to determine which events deliver the greatest return on investment. The funding will support geographic expansion, including establishing a London-based team, and product development. Vendelux plans to more than double its workforce by the end of 2024 and develop intelligence solutions for conference organisers.
Vendelux has launched a delegate marketing platform to empower event organisers to grow their audiences with unmatched precision and speed.
Humana’s CenterWell healthcare services business Tuesday said it would expand beyond its traditional. More home-delivery pharmacy services business and will begin filling and shipping orders for the popular GLP-1 weight loss drug Wegovy that are prescribed through three telehealth companies: Hims & Hers Health, Inc., LifeMD and Ro. In this photo are images of Novo Nordisk's Wegovy, an injectable prescription weight loss medicine that has helped people with obesity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty ImagesHumana is the latest health insurer to expand into the fast-growing and lucrative business of direct-to-patient specialty pharmacy as demand grows for popular GLP-1 weight loss drugs.Humana’s CenterWell healthcare services business Tuesday said it would expand beyond its traditional home-delivery pharmacy services business and will begin filling and shipping orders for the popular GLP-1 weight loss drug Wegovy that are prescribed through three telehealth companies: Hims & Hers Health, Inc., LifeMD and Ro.The partnership was disclosed by Humana and Novo Nordisk that CenterWell Pharmacy will be its fulfillment partner for NovoCare, a pharmacy the drug maker launched a month ago to provide ”direct-to-patient, convenient home shipments of all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients,” Novo Nordisk said last month.CenterWell pharmacy’s partnership with Novo Nordisk is directed at cash-paying consumers, or what the industry calls “self-pay” patients, who don’t have health insurance coverage for anti-obesity drugs, which are dropping in price but even with discounts cost several hundred dollars an injection.“Under the arrangement, CenterWell is helping consumers benefit from reduced cost and convenient access to safe and effective brand-name medications,” CenterWell pharmacy senior vice president Guillermo Sollberger said in a statement released during the annual at Asembia ASX25, which draws more than 8,000 companies tied to the specialty pharmacy industry this week to Las Vegas.The partnership also comes in the wake of the Trump White House’s decision earlier this month to scrap a Biden administration proposal to have Medicare health plans for seniors and Medicaid insurance for low-income Americans cover weight loss drugs such as Novo Nordisk’s Wegovy.CenterWell and Novo Nordisk see “direct-to-patient” partnerships as a way to expand access to those without health insurance coverage for certain prescriptions. Novocare follows a similar effort launched last year called LillyDirect, a direct-to-patient effort from Eli Lilly, maker of the GLP-1 drug Zepbound.“NovoCare Pharmacy is a direct-to-patient delivery option that offers cash-paying patients the GLP-1 medication, Wegovy, at a reduced cost of $499 per month,” Sollberger said. “Under the arrangement, CenterWell is helping consumers benefit from reduced cost and convenient access to safe and effective brand-name medications.”It’s the latest health insurer to expand deeper into specialty pharmacy.Already, UnitedHealth Group’s OptumRx and CVS Health, which owns the health insurer Aetna, have expanded more into specialty pharmacy